Retatrutide Isn't a Weight Loss Drug — Here's What It Really Does (Weightloss Dr. Explains)
A solo physician explainer arguing retatrutide matters beyond weight loss, walking through its three-receptor mechanism and reported liver, joint, lipid, kidney and early brain data.
With Dr. Kevin Joseph (DO)
Key moments
Tap a moment to play the video from there.
- 0:00Why weight loss undersells retatrutideJoseph previews the organ-level results he plans to cover, from fatty liver to knee pain to kidneys, and introduces himself as an obesity medicine physician.
- 1:02Three receptors in one injectionHe describes retatrutide as a weekly Eli Lilly injection acting on GLP-1, GIP and glucagon receptors, and says it is nearly nine times stronger than the natural hormone on GIP.
- 3:10What the glucagon switch addsJoseph says glucagon activation, combined with the other two, raises calories burned and shifts the liver toward burning fat and making less of it.
- 4:08Phase two and three weight lossHe cites 24% average loss at 12 mg in phase two and about 29% at 12 mg in TRIUMPH 4 at 68 weeks.
- 6:12Liver fat results from Nature MedicineHe walks through the 98-person study, reporting liver fat reductions of up to 86% and 93% of people on the top dose under 5% fat at 48 weeks.
- 8:44Knee arthritis pain in TRIUMPH 4Joseph reports pain reduced by over 75% at 12 mg across 445 people, and says the effect exceeded what weight loss alone would predict.
- 10:11Lipid data from 338 peopleHe cites Eli Lilly data showing non-HDL cholesterol down up to 27%, apoB down up to 24% and triglycerides down up to 40.6%.
- 11:12Kidney findings and TRANSCEND CKDHe describes improved filtering and less urine protein at higher doses in pooled trial data, and the ongoing TRANSCEND CKD trial.
- 12:23Sleep apnea and brain healthJoseph says sleep apnea is under study and that brain protection evidence is preclinical, calling it the least proven part of his case.
- 14:19Conclusion and safety caveatsHe restates his case, notes retatrutide is investigational and not FDA approved, and flags dysesthesia seen in TRIUMPH 4.
What the video says
Dr. Kevin Joseph, who says he specializes in obesity medicine and peptide therapy, argues that retatrutide should not be judged only by the scale. He describes it as a once-a-week injection from Eli Lilly that acts on three receptors at once: GLP-1, GIP and glucagon. He says the glucagon receptor is the distinctive part, because activating it alongside the other two raises calories burned and tells the liver to burn fat and make less of it.
Joseph first covers weight loss. He cites phase two results of an average 24% body weight loss at 12 mg after 48 weeks, and phase three TRIUMPH 4 results of about 26% at 9 mg and about 29% at 12 mg after 68 weeks. He says the 29% is the largest loss reported for any drug in a phase three trial.
The bulk of the video covers other organs. For the liver, he describes a Nature Medicine study led by Arun Sanyal in 98 people, with liver fat falling 82% at 12 mg after 24 weeks and 93% of people on the top dose reaching under 5% fat by 48 weeks. He then cites TRIUMPH 4 knee arthritis pain reductions of over 75% at 12 mg, Eli Lilly lipid data (triglycerides down up to 40.6%, apoB down up to 24%), and kidney filtering and urine protein findings from a pooled analysis, with the TRANSCEND CKD trial now running.
He closes with sleep apnea and brain health, and says the brain material is the least proven part, resting on preclinical studies and a review noting no human brain studies yet. He states that retatrutide is investigational and not FDA approved, and he flags a nerve side effect called dysesthesia seen in TRIUMPH 4. The video is one physician's enthusiastic reading of published and company-reported data, not a neutral review.
On each compound
Retatrutide1:02
Joseph describes it as a once-a-week triple agonist of the GLP-1, GIP and glucagon receptors from Eli Lilly. He reports large weight loss, liver fat, knee pain, lipid and kidney findings, and says it remains investigational with dysesthesia flagged as a safety question.
See how your DNA reads RetatrutideTirzepatide4:08
Joseph uses tirzepatide as a comparator, saying its top dose has landed around 22% weight loss and that retatrutide beat it in trials. He also says tirzepatide cut sleep apnea events by roughly half and is FDA approved for that use.
See how your DNA reads TirzepatideSemaglutide1:02
Joseph mentions semaglutide as a one-receptor drug and as a weight loss comparator, saying it landed at roughly 15% or so, which he places below retatrutide.
See how your DNA reads SemaglutideWhat this video doesn’t settle
- The video does not establish whether liver scarring actually improves, since Joseph says the cited liver study took no biopsies and the large outcomes trial is not due until around 2029 or 2030.
- Brain-health claims rest on preclinical studies and a review, and Joseph himself says no human brain studies exist yet.
- Joseph says the knee pain trial cannot separate weight loss from any direct anti-inflammatory effect.
Questions this video answers
How much weight did people lose on retatrutide in the trials Dr. Kevin Joseph cites?
Joseph says phase two participants on 12 mg lost an average of 24% of body weight at 48 weeks. He says phase three TRIUMPH 4 participants lost about 26% on 9 mg and about 29% on 12 mg at 68 weeks.
How does retatrutide work according to this video?
Joseph says it activates the GLP-1, GIP and glucagon receptors at once. He says the glucagon part raises calories burned and tells the liver to burn fat and make less of it.
What does Dr. Joseph say retatrutide did for fatty liver?
He cites a Nature Medicine study of 98 people with at least 10% liver fat, where fat fell up to 86% at 48 weeks. He says 93% of people on the top dose had under 5% liver fat, though the study had no biopsies to confirm scarring changes.
Is retatrutide approved, and what safety concerns does the video mention?
Joseph says it is still investigational and not FDA approved, with big trials still running. He flags a nerve side effect called dysesthesia that showed up in TRIUMPH 4.
Video by Dr. Kevin Joseph, DO on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
